The invention provides oncogenomic methods for detecting tumors by identifying circulating tumor DNA. A patient-specific reference directed acyclic graph (DAG) represents known human genomic sequences and non-tumor DNA from the patient as well as known tumor-associated mutations. Sequence reads from cell-free plasma DNA from the patient are mapped to the patient-specific genomic reference graph. Any of the known tumor-associated mutations found in the reads and any de novo mutations found in the reads are reported as the patient's tumor mutation burden.

The invention provides oncogenomic methods for detecting tumors by identifying circulating tumor DNA. A patient-specific reference directed acyclic graph (DAG) represents known human genomic sequences and non-tumor DNA from the patient as well as known tumor-associated mutations. Sequence reads from cell-free plasma DNA from the patient are mapped to the patient-specific genomic reference graph. Any of the known tumor-associated mutations found in the reads and any de novo mutations found in the reads are reported as the patient's tumor mutation burden.

The invention relates to a method for determining whether a subject with an infection has a viral infection. The invention further relates to method for determining the cellular immune response to a viral infection or a vaccine. The methods may be performed on a blood sample obtained from a subject, and is based on the finding that specific cellular signaling pathways are active. The invention further relates to components for performing the methods and use of those components in a method of diagnosis.

Methods for identifying cancer patients amenable to anti-cancer immunotherapy are provided along with methods of monitoring cancer therapy. Also provided are methods of treating cancer patients amenable to anti-cancer immunotherapy. The methods involve determining the level of CD127 <low> PD-1 <low> T cells. The patients are treated with an immune checkpoint inhibitor, such as an anti-CTLA-4 antibody, e.g. ipilimumab.

Methods for identifying cancer patients amenable to anti-cancer immunotherapy are provided along with methods of monitoring cancer therapy. Also provided are methods of treating cancer patients amenable to anti-cancer immunotherapy. The methods involve determining the level of CD127 <low> PD-1 <low> T cells. The patients are treated with an immune checkpoint inhibitor, such as an anti-CTLA-4 antibody, e.g. ipilimumab.

A random sequence generation of defined values may be provided. A method comprises pre-loading a RAM block with an initial list comprising the defined values of a sequence of values to be updated, and shuffling the defined values of the sequence using a counter and a random offset for indices in the list.

Analysis of genetic disease progression may be provided. Data about a set of molecular status may be received. A dynamic prediction model of molecular interactions may be provided over time. The molecular statuses of the set over time may be determined using the dynamic prediction model. The determined molecular statuses may be clustered by applying an interaction-aware metric for the analysis of the genetic disease progression.

Analysis of genetic disease progression may be provided. Data about a set of molecular status may be received. A dynamic prediction model of molecular interactions may be provided over time. The molecular statuses of the set over time may be determined using the dynamic prediction model. The determined molecular statuses may be clustered by applying an interaction-aware metric for the analysis of the genetic disease progression.

The present disclosure relates to cell populations and systems for detection of compounds in an environment. Specifically the disclosure relates to methods for generating reproducible genome-wide edited populations of microbes that display novel, defined, and reproducible phenotypes when exposed to one or more chemicals. In some applications, such phenotypes are read out by barcode amplicon and compared against population fingerprints. In other applications digital information is stored in such populations of microorganisms. The digital information can be retrieved from the microorganisms with Boolean logic.

The present disclosure discloses a DNA matrix processing method based on a combined restriction digestion mechanism, including the following steps: constructing a single auxiliary strand-mediated combined restriction digestion mechanism; introducing an auxiliary strand based on the single auxiliary strand-mediated combined restriction digestion mechanism, to obtain a dual auxiliary strands-mediated combined restriction digestion mechanism; and constructing DNA matrix processing and a weighted sum of Boolean matrix multiplication with the dual auxiliary strands-mediated combined restriction digestion mechanism; in which the two auxiliary strands are directly used as elements involved in the matrix processing, and the 2N auxiliary strands are combined into N.sup.2 four-pronged restriction digestion structures in the presence of E6 type DNAzymes to cleave N.sup.2 substrate strands. Meanwhile, due to high-efficiency catalysis and specific recognition, the E6 type DNAzymes make the matrix processing rapid and accurate.